



Press Release

ABIONYX Pharma announces its financial agenda for the year 2020

Toulouse, FRANCE, Lakeland MI, UNITED-STATES, January 28, 2020, 6:00 pm CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2020.

Events	Date*
Cash position and activity update for Q4 2019	February 4, 2020
2019 Annual Results	March 19, 2020
Cash position and activity update for Q1 2020	April 23, 2020
Cash position and activity update for Q2 2020	July 23, 2020
2020 Half Year Results	September 10, 2020
Cash position and activity update for Q3 2020	October 22, 2020

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.

Contacts:

NewCap

Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Nicolas Merigeau
abionyx@newcap.eu
+33 (0)1 44 71 94 98